Xiangkun Dai

Xiangkun Dai

Auto-generated profile, based on publicly available information

Xiangkun Dai

Department of Radiotherapy The First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital Beijing CHN

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in BMC Cancer
Verified
Journal Article
Open access
PDF file
JWJinyuan Wang
Jinyuan Wang
QZQingzeng Zheng
Qingzeng Zheng
YWYanping Wang
Yanping Wang
CWChengcheng Wang
Chengcheng Wang
SXShouping Xu
Shouping Xu
XDXiangkun Dai
Xiangkun Dai
To evaluate the dosimetric characteristics of ZAP-X stereotactic radiosurgery (SRS) for single brain metastasis by comparing with two mature SRS platforms. Thirteen patients with single brain metastasis treated with CyberKnife (CK) G4 were selected retrospectively. The prescription dose for the planning target volume (PTV) was 18–24 Gy for 1–3 fractions. The PTV volume ranged from 0.44 to 11.52 cc.Treatment plans of thirteen patients were replanned using the ZAP-X plan system and the Gamma Knife (GK) ICON plan system with the same prescription dose and organs at risk (OARs) constraints. The prescription dose of PTV was normalized to 70% for both ZAP-X and CK, while it was 50% for GK. The dosimetric parameters of three groups included the plan characteristics (CI, GI, GSI, beams, MUs, treatment time), PTV (D2, D95, D98, Dmin, Dmean, Coverage), brain tissue (volume of 100%-10% prescription dose irradiation V100%-V10%, Dmean) and other OARs (Dmax, Dmean),all of these were compared and evaluated. All data were read and analyzed with MIM Maestro. One-way ANOVA or a multisample Friedman rank sum test was performed, where p < 0.05 indicated significant differences. The CI of GK was significantly lower than that of ZAP-X and CK. Regarding the mean value, ZAP-X had a lower GI and higher GSI, but there was no significant difference among the three groups. The MUs of ZAP-X were significantly lower than those of CK, and the mean value of the treatment time of ZAP-X was significantly shorter than that of CK. For PTV, the D95, D98, and target coverage of CK were higher, while the mean of Dmin of GK was significantly lower than that of CK and ZAP-X. For brain tissue, ZAP-X showed a smaller volume from V100% to V20%; the statistical results of V60% and V50% showed a difference between ZAP-X and GK, while the V40% and V30% showed a significant difference between ZAP-X and the other two groups; V10% and Dmean indicated that GK was better. Excluding the Dmax of the brainstem, right optic nerve and optic chiasm, the mean value of all other OARs was less than 1 Gy. For the brainstem, GK and ZAP-X had better protection, especially at the maximum dose. For the SRS treating single brain metastasis, all three treatment devices, ZAP-X system, CyberKnife G4 system, and GammaKnife system, could meet clinical treatment requirements. The newly platform ZAP-X could provide a high-quality plan equivalent to or even better than CyberKnife and Gamma Knife, with ZAP-X presenting a certain dose advantage, especially with a more conformal dose distribution and better protection for brain tissue. As the ZAP-X systems get continuous improvements and upgrades, they may become a new SRS platform for the treatment of brain metastasis.

2 May 2025 in Cureus
Verified
Journal Article
Open access
PDF file
SGShanshan Gu
Shanshan Gu
XLXiaoliang Liu
Xiaoliang Liu
ZJZhongjian Ju
Zhongjian Ju
HWHaiyang Wang
Haiyang Wang
JSJinglin Sun
Jinglin Sun
LDLehui DU
Lehui DU
This case describes an 81-year-old male patient with poorly differentiated lung adenocarcinoma, complicated by severe chronic obstructive pulmonary disease (COPD) and a history of coronary stenting. The patient underwent CyberKnife (Accuray Inc., Madison, WI, United States) stereotactic body radiotherapy (SBRT) with synchrony respiratory tracking and staged radiotherapy. The patient received staged radiotherapy delivered in two sequential phases: phase I (30 Gy in three fractions) was administered from November 18 to 24, 2022, followed by phase II (30 Gy in three fractions) initiated on February 20, 2023, after a 12-week intermission for therapeutic response assessment and normal tissue recovery. The cumulative prescription totaled 60 Gy in six fractions (equivalent dose in 2-Gy fractions (EQD2) = 120 Gy, α/β = 10), with strict adherence to organ-at-risk (OAR) constraints. Through fiducial marker implantation and dynamic dose optimization, the ipsilateral lung V20 was reduced from 3.35% to 1.63%. No severe treatment-related toxicities (≥ grade 2) were observed during or after the treatment period. At a three-month follow-up, the tumor volume decreased by 79% (117.04 cm³ → 24.26 cm³), demonstrating significant local control. This case provides a practical reference for personalized radiotherapy in elderly patients with cardiopulmonary comorbidities.

21 June 2025 in Cureus
Verified
Journal Article
Open access
PDF file
CWChengcheng Wang
Chengcheng Wang
JWJinyuan Wang
Jinyuan Wang
JBJingmin Bai
Jingmin Bai
LPLongsheng Pan
Longsheng Pan
PXPengfei Xu
Pengfei Xu
XDXiangkun Dai
Xiangkun Dai
This study evaluated the clinical benefit of the application of the ZAP-X stereotactic radiosurgery (SRS) system in the treatment of glomus jugulare tumors. Two patients with recurrent or progressive glomus jugulare tumors underwent treatment with the ZAP-X SRS system. Analysis of clinical treatment processes and follow-up data over a period of up to three years revealed that after treatment with the ZAP-X system, the tumor volumes significantly reduced, and no severe radiation therapy-related complications were observed. These findings highlight the potential clinical benefits of the ZAP-X system in the treatment of complex skull base tumors.